Use of the Hansen Medical System in Patients With Atrial Fibrillation (ARTISAN AF)

This study is currently recruiting participants.
Verified August 2012 by Hansen Medical
Sponsor:
Information provided by (Responsible Party):
Hansen Medical
ClinicalTrials.gov Identifier:
NCT01122173
First received: May 10, 2010
Last updated: August 22, 2012
Last verified: August 2012
  Purpose

The purpose of this study is to assess the safety and performance of the Hansen Medical Sensei Robotic System and Artisan Catheter when used to robotically manipulate the Biosense ThermoCool ablation catheter for the treatment of atrial fibrillation (irregular heartbeats originating in the upper chambers of the heart). The Biosense ThermoCool catheter is FDA approved for use in ablation therapy. The Hansen Medical Robotic Sensei System and Artisan catheter is approved in Europe for use during ablation procedures. This system has been used to treat atrial fibrillation in over 1000 patients worldwide by navigating existing, approved ablation catheters. In the US the Hansen Sensei System with Artisan catheter has FDA clearance as a robotic delivery system to facilitate manipulation, positioning and control of catheters used to collect electrophysiological data within the heart atria (upper chambers or the heart) but has not been studied or approved in the US for use in ablation treatment This study is looking to show safety, compatibility and effectiveness when the Hansen system is used in conjunction with the ThermoCool ablation catheter in the treatment of atrial fibrillation. This will be done by to either treatment with manual delivery of the ThermoCool ablation catheter or treatment with robotic delivery of the of the ThermoCool ablation catheter.


Condition Intervention
Paroxysmal Atrial Fibrillation
Device: RF Ablation

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Randomized Study of the Hansen System for Introducing and Positioning the Thermocool Catheter in Patients With Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by Hansen Medical:

Primary Outcome Measures:
  • The absence of early onset (within 7 days of the ablation procedure) of all Serious Adverse Events as defined in the protocol. [ Time Frame: 0 - 7 days ] [ Designated as safety issue: Yes ]
  • Freedom from symptomatic atrial fibrillation from days 91-365 (chronic procedural success). [ Time Frame: 91 - 365 days ] [ Designated as safety issue: No ]
  • Absence of esophageal injury or pulmonary vein stenosis through day 365. [ Time Frame: 0 - 365 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Freedom from serious adverse events (SAEs) from day 8 through day 365. [ Time Frame: 8 - 365 days ] [ Designated as safety issue: Yes ]
  • Acute pulmonary vein isolation of at least three out of four veins, as documented by testing entrance block, during the procedure. [ Time Frame: 0 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: May 2010
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Robotic catheter manipulation for RF Ablation
Introduce and position ThermoCool remotely through the Artisan Control Catheter.
Device: RF Ablation
PV isolation is the required ablation procedure.
Other Names:
  • Sensei X Robotic Catheter System
  • Artisan Control Catheter
  • NaviStar ThermoCool
Active Comparator: Manual catheter manipulation for RF Ablation
Introduce and position the ThermoCool manually.
Device: RF Ablation
PV isolation is the required ablation procedure.
Other Names:
  • Sensei X Robotic Catheter System
  • Artisan Control Catheter
  • NaviStar ThermoCool

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with paroxysmal atrial fibrillation who have had two or more spontaneously terminating episodes of atrial fibrillation, that last longer than 30 seconds and shorter than 7 days, in the nine months prior to enrollment. At least one episode must be documented with EKG, TTM, Holter monitor, or telemetry.
  2. Failure of at least one Class I - IV anti-arrhythmic drug (AAD) for PAF as evidenced by recurrent symptomatic PAF, or intolerable side effects due to AAD. AADs are defined in Appendix B.
  3. Signed informed consent.
  4. Age 18 years or older
  5. Able and willing to comply with all pre-, post-, and follow-up testing and requirements.

Exclusion Criteria:

  1. Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  2. Previous ablation for atrial fibrillation.
  3. Atrial fibrillation episodes that last less than 7 days and are terminated by cardioversion.
  4. Previous valvular cardiac surgery procedure.
  5. Cardiac artery bypass graft procedure within the previous 180 days.
  6. Previous septal defect repair.
  7. Expecting cardiac transplantation or other cardiac surgery within the next 180 days.
  8. Coronary PTCA/stenting within the previous 180 days.
  9. Documented left atrial thrombus on ultrasound imaging (TEE).
  10. Documented history of a thrombo-embolic event within the previous year.
  11. Diagnosed atrial myxoma.
  12. Presence of an implanted ICD.
  13. Presence of permanent pacing leads.
  14. Significant restrictive, constrictive, or chronic obstructive pulmonary disease or any other disease or malfunction of the lungs or respiratory system with chronic symptoms.
  15. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
  16. Women who are pregnant.
  17. Acute illness or active infection at time of index procedure documented by either pain, fever, drainage, positive culture and/or leukocytosis (WBC > 11.000 mm3) for which antibiotics have been or will be prescribed.
  18. Creatinine > 2.5 mg/dl (or > 221 µmol/L).
  19. Unstable angina.
  20. Myocardial infarction within the previous 60 days.
  21. Left ventricular ejection fraction less than 40%
  22. History of blood clotting or bleeding abnormalities.
  23. Contraindication to anticoagulation.
  24. Contraindication to computed tomography or magnetic resonance imaging procedures.
  25. Life expectancy less than 1 year.
  26. Enrollment in another investigational study.
  27. Uncontrolled heart failure (NYHA class III or IV heart failure).
  28. Presence of an intramural thrombus, tumor, or other abnormality that precludes catheter introduction or positioning.
  29. Presence of a condition that precludes vascular access.
  30. Left Atrial size ≥ 50mm.
  31. INR greater than 3.0 within 24 hours of procedure.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01122173

Locations
United States, California
Stanford Univeristy Medical Center Recruiting
Stanford, California, United States, 94305
Contact: Linda Norton, RN     650-725-5597     lnorton@stanfordmed.org    
Principal Investigator: Amin Al-Ahmad, MD            
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Kelly Wock     507-255-7456     wock.kelly@mayo.edu    
Principal Investigator: Douglas Packer, MD            
United States, New York
Stony Brook Univeristy Medical Center Recruiting
Stony Brook, New York, United States, 11794
Contact: Joyce Quick, PA     631-444-8485     Joyce.Quick@stonybrookmedicine.edu    
Principal Investigator: Eric Rashba, MD            
United States, North Carolina
Duke University Health System Recruiting
Durham, North Carolina, United States, 27710
Contact: Debbie Hickey     919-668-3524     deborah.hickey@duke.edu    
Principal Investigator: Patrick Hranitzky, MD            
United States, South Carolina
Greenville Memorial Hospital Recruiting
Greenville, South Carolina, United States, 29605
Contact: Erikia Channell     864-455-2288     echannell@ghs.org    
Contact: Maureen Coyne     864-455-7727     mcoyne@ghs.org    
Principal Investigator: Donald Rubenstein, MD            
Sub-Investigator: Joseph Manfredi, MD            
United States, Texas
Texas Cardiac Arrhythmia Research Foundation (TCARF) Recruiting
Austin, Texas, United States, 78705
Contact: Deb Cardinal     512-458-9410     dscardinal@austinheartbeat.com    
Principal Investigator: G. J. Gallinghouse, M.D.            
Houston Methodist Recruiting
Houston, Texas, United States, 77030
Contact: Melinda Tindel     713-441-3248     MTindel@tmhs.org    
Principal Investigator: Miguel Valderrábano, MD            
United States, Virginia
Univeristy of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Mary Jane Strickland     434-982-6401     MJS7W@hscmail.mcc.virginia.edu    
Principal Investigator: J. Michael Mangrum, MD            
Sponsors and Collaborators
Hansen Medical
Investigators
Principal Investigator: Andrea Natale, M.D. Texas Cardiac Arrhythmia Research Foundation
Study Director: Dale Bergman Hansen Medical, Inc.
  More Information

No publications provided

Responsible Party: Hansen Medical
ClinicalTrials.gov Identifier: NCT01122173     History of Changes
Other Study ID Numbers: HMP010
Study First Received: May 10, 2010
Last Updated: August 22, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Hansen Medical:
Atrial Fibrillation
Robotic Control
Remote Control

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 19, 2013